Literature DB >> 8998855

Mitochondrial changes in muscle phosphoglycerate kinase deficiency.

J M Schröder1, R Dodel, J Weis, I Stefanidis, H Reichmann.   

Abstract

X-linked phosphoglycerate kinase (PGK) deficiency is a rare disorder which affects the glycolytic pathway and leads to reduced ATP production. Clinically, PGK deficiency is often associated with nonspherocytic hemolytic anemia and symptoms caused by disturbances of the central nervous system. In addition, myopathy characterized by weakness, cramps, intolerance to exercise, and myoglobinuria has been described in a few cases. We here report on a 23-year-old man who presented with episodes of muscular weakness, cramps, rhabdomyolysis, and renal failure induced by intensive physical exercise. Biochemical analysis of muscle specimens disclosed markedly reduced PGK activity (11.5% compared to normal controls). A moderate increase of glycogen was seen in numerous muscle fibers. Mitochondria in muscle fibers and endothelial cells showed accumulations of glycogen. In muscle fibers unusually large matrix granules were present in several mitochondria. A sural nerve biopsy disclosed scattered large hypomyelinated axons without evidence of demyelination and remyelination. These findings indicate involvement of mitochondria in this case of symptomatic PGK deficiency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8998855

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  2 in total

1.  Clinical Severity of PGK1 Deficiency Due To a Novel p.E120K Substitution Is Exacerbated by Co-inheritance of a Subclinical Translocation t(3;14)(q26.33;q12), Disrupting NUBPL Gene.

Authors:  Dezső David; Lígia S Almeida; Maristella Maggi; Carlos Araújo; Stefan Imreh; Giovanna Valentini; György Fekete; Irén Haltrich
Journal:  JIMD Rep       Date:  2015-03-27

Review 2.  Neuropathology of Charcot-Marie-Tooth and related disorders.

Authors:  J Michael Schröder
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.